CSEM and ClexBio unveil bioreactor to advance cardiovascular treatment

27 February 2024 13:11

Greater Geneva Bern

Neuchâtel/Oslo - CSEM and ClexBio, a Nordic startup specializing in regenerative medicine, have developed a novel bioreactor capable of cultivating human veins in the laboratory.

The collaboration between CSEM and ClexBio has yielded a prototype bioreactor designed for the production of functional vein implants from stem-cell-derived human tissue. These implants are intended to seamlessly integrate into the patient’s body, transforming into living tissue over time.

Leveraging ClexBio’s expertise in regenerative medicine and hydrogels, alongside CSEM’s prowess in automation and micro physiological systems, the partnership has brought to life a biodegradable matrix capable of creating human tissue.

ClexBio introduces its platform technology, VivoSet, a cell-biomaterial formulation that engineers tissues with complex architectures, including veins. This technology, combined with CSEM’s innovative approach to bioreactor design, replicates the natural tubular structure of veins, fostering the production of tissue-engineered vein grafts. These grafts are designed to be implanted “off the shelf,” offering a regenerative solution devoid of immune response, thus heralding a potential breakthrough in modern medicine.

The project, dubbed Supervene, aims to automate the fabrication process for regenerative medicine, transitioning from laboratory to clinical application. “VivoSet is a new technology that can unlock the incredible potential of novel cell therapies,” said Stéphanie Boder-Pasche, Senior Project Manager at CSEM. This sentiment was echoed by Gilles Weder, Head of Research & BD at CSEM, who underscored the necessity of a closed, automated bio-manufacturing system for producing such implants.

With the system now developed, ClexBio will undertake further pre-clinical testing in larger animal models, with the ultimate goal of conducting in-human studies. CEO & Co-Founder of ClexBio, Armend Håti, highlighted the significance of this development: “We are truly excited about the paradigm shift this may usher in for human surgery and the treatment of damaged tissues.” ggba

Swiss Pavilion Digital

Previous newsletters